NCT04439006 2023-12-26
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
Clinical Trials
1 trialsMonoclonal Gammopathy of Undetermined Significance × ibrutinib × Other hematologic neoplasm × Clear all